Said Bolorforosh - Haemonetics Executive Vice President, Chief Technology Officer
HAE Stock | USD 84.09 2.45 3.00% |
President
Mr. Said Bolorforosh, Ph.D., was appointed Executive Vice President and Chief Technology Officer of the Company effective May 21, 2018. Prior to joining Haemonetics, Bolorforosh was President, Ultrasound, at Siemens Healthcare, where he delivered positive growth and market share gains by rebuilding the product portfolio, improving sales and distribution capabilities and optimizing gotomarket strategies globally. He previously served as Vice President and General Manager of Intensive Insulin Delivery, Vice President of RD and Chief Technology Officer for Medtronic Diabetes division, leading PL as well as technology and product development. From 2004 to 2014, Bolorforosh held positions of increasing responsibility at General Electric Ultrasound division, including Global General Manager, Growth and Strategy Global General Manager, Point of Care and Chief Technology Officer. Bolorforosh received a BS in Electronic and Electrical Engineering from Cardiff University, University of Wales, and a doctorate in Electronic Engineering from University of London, King College London. He holds numerous patents and publications. since 2018.
Age | 56 |
Tenure | 6 years |
Professional Marks | Ph.D |
Address | 125 Summer Street, Boston, MA, United States, 02110 |
Phone | 781 848 7100 |
Web | https://www.haemonetics.com |
Haemonetics Management Efficiency
The company has Return on Asset of 0.0612 % which means that on every $100 spent on assets, it made $0.0612 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1472 %, implying that it generated $0.1472 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 929.4 M, whereas Other Current Assets are forecasted to decline to about 35.8 M.Similar Executives
Showing other executives | PRESIDENT Age | ||
William McDowell | Cigna Corp | N/A | |
Everett Neville | Cigna Corp | 59 | |
Brian Caveney | Laboratory | 47 | |
John Murabito | Cigna Corp | 62 | |
Scott Frommer | Laboratory | N/A | |
Matt Perlberg | Cigna Corp | N/A | |
John Pepia | Mednax Inc | 61 | |
Michael Stanley | Mednax Inc | 68 | |
Marcel Roche | Guardant Health | N/A | |
Peter Wilkinson | Laboratory | 52 | |
William Klitgaard | Laboratory | 61 | |
Stephen Farber | Mednax Inc | 49 | |
Charles Lynch | Mednax Inc | N/A | |
Stephen Anderson | Laboratory | N/A | |
Brian Evanko | Cigna Corp | 47 | |
Mark Boxer | Cigna Corp | 59 | |
David Guilmette | Cigna Corp | 51 | |
Dean Mirabella | Cigna Corp | N/A | |
Noelle Eder | Cigna Corp | 54 | |
Kristen Lauria | Cigna Corp | 51 | |
Lance Berberian | Laboratory | 61 |
Management Performance
Return On Equity | 0.15 | ||||
Return On Asset | 0.0612 |
Haemonetics Leadership Team
Elected by the shareholders, the Haemonetics' board of directors comprises two types of representatives: Haemonetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haemonetics. The board's role is to monitor Haemonetics' management team and ensure that shareholders' interests are well served. Haemonetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haemonetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Susan Hanlon, Chief Accounting Officer and VP of Fin. | ||
Stewart Strong, Pres Hospital | ||
Rajeev Varma, Senior Development | ||
William Burke, Chief Financial Officer, Executive Vice President | ||
Olga Guyette, Director Relations | ||
Carla Burigatto, VP Communications | ||
Laurie Miller, Senior Officer | ||
Anthony Gazikas, CIO and VP | ||
Susan Foote, Independent Director | ||
David Helsel, Executive Vice President - Global Manufacturing | ||
Seyed Mirsaid, Executive Vice President, Chief Technology Officer | ||
Ronald Gelbman, Interim CEO, Lead Director, Chairman of Governance and Compliance Committee and Member of Audit Committee | ||
Robert Abernathy, Independent Director | ||
Neil Ryding, Executive Vice President Global Operations | ||
Ellen Zane, Non-Executive Independent Chairman of the Board | ||
David Wilson, President - Plasma Business Unit | ||
Sandra Jesse, Vice President Chief Legal Officer | ||
Kent Davies, COO | ||
Christopher Lindop, CFO and Executive VP of Bus. Devel. | ||
Claire Pomeroy, Independent Director | ||
Michelle Basil, Executive Vice President General Counsel | ||
Christopher Simon, President, Chief Executive Officer, Director | ||
Catherine Burzik, Independent Director | ||
Mark Kroll, Independent Director | ||
Dan Goldstein, Principal Accounting Officer | ||
James Darecca, Executive Vice President, Chief Financial Officer | ||
James CPA, Executive CFO | ||
Jacqueline Scanlan, Senior Vice President - Human Resources | ||
Josep Llorens, Senior Vice President - Global Manufacturing and Supply Chain | ||
Farris Maunsell, Chief VP | ||
Jonathan White, Chief Science and Technology Officer | ||
Gerry Gould, IR Contact Officer | ||
Jan MD, Senior Officer | ||
Richard Meelia, Non-Executive Independent Chairman of the Board | ||
Anila Lingamneni, Executive Vice President, Chief Technology Officer | ||
Francis Tan, Sr Planning | ||
Byron Selman, President - Global Markets | ||
Charles Dockendorff, Independent Director | ||
Thomas McCurdy, President - Global Plasma | ||
Said Bolorforosh, Executive Vice President, Chief Technology Officer | ||
Ronald Merriman, Independent Director | ||
Pedro Granadillo, Independent Director | ||
Lloyd Johnson, Director | ||
Michael Coyle, Independent Director |
Haemonetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haemonetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.15 | ||||
Return On Asset | 0.0612 | ||||
Profit Margin | 0.1 % | ||||
Operating Margin | 0.16 % | ||||
Current Valuation | 4.82 B | ||||
Shares Outstanding | 50.79 M | ||||
Shares Owned By Insiders | 0.76 % | ||||
Shares Owned By Institutions | 99.24 % | ||||
Number Of Shares Shorted | 1.96 M | ||||
Price To Earning | 50.35 X |
Haemonetics Investors Sentiment
The influence of Haemonetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Haemonetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Haemonetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Haemonetics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Haemonetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Haemonetics' short interest history, or implied volatility extrapolated from Haemonetics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Transaction History View history of all your transactions and understand their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 2.46 | Revenue Per Share 25.092 | Quarterly Revenue Growth 0.101 | Return On Assets 0.0612 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.